The effect of Vorinostat (SAHA) and ERL on the expression profile of P21 and PARP in MCF-7 breast cancer cell line

Abstract

The fight to defeat cancer is viewed as the greatest challenge of modernistic medicine. Despite many forms of cancers, breast cancer still the most frequently diagnosed one among females worldwide, numerous chemotherapeutic drugs have been developed to overcome this type of cancer. At present, much clinical interest is focused on combination with HDAC inhibitors, those combination therapy has the greatest biological rationale. In the current study, the antiproliferative effect of a combination of Vorinostat (SAHA) and Erlotinib in breast cancer cell line (MCF7) were evaluated. Cytotoxicity effect of the drugs single and in combination was measured by MTT assay. As well, the expression levels of P21 and PARP genes was measured by qRT-PCR after 24 h of treatment. MTT assay exposed that combination of erlotinib and vorinostat drugs synergistically induce cytotoxic effect in breast cancer cell lines. qPCR results demonstrated synergistic upregulation in the mRNA levels of P21 and PARP at the used concentrations. Our data provide indication that synergistic antiproliferative effects of Erlotinib and Vorinostat are related to the up-regulation of P21 and PARP genes and propose that the combination therapy may have therapeutic value in breast cancer treatment.